Conference spotlight
نویسندگان
چکیده
منابع مشابه
A Spotlight on Spotlight
In this paper, we have made an attempt to take a look under the hood of Spotlight and understand some of the following questions amongst others: • How well-integrated is Spotlight with the file system? • How reliable is the interface between Spotlight and the file system? • Is live update a myth or a reality under heavy file system activity? Based on our experiments, it seems that Spotlight is ...
متن کاملSpotlight.
In this issue All accredited nursing care centers must complete ICM tool; standards available on ICM profile AFRH vision proves, ‘There’s no place like Home’ Free e-learning module aims to reduce infections in long term care settings Be vigilant about environmental hazards that affect patient and resident safety R3 Report explains new memory care accreditation requirements for nursing care cent...
متن کاملRE@21 spotlight: Most influential papers from the requirements engineering conference
Since 2003, an award has been presented annually at the IEEE International Requirements Engineering Conference for the Most Influential Paper presented at the conference 10 years previously. In 2013, we celebrate 21 years of the Require ments Engineering Conference, and we use this as an opportunity to reflect on the Most Influential Papers to date. Two sessions of the 2013 conference highligh...
متن کاملSpotlight- Molecular iodine
Mayuri M. Naik was born in 1988 in Curchorem, Goa (India). She completed her B.Sc. from Government College of arts, science and commerce, Quepem-Goa in 2008. She received her M.Sc. degree in organic chemistry from Goa University in 2010. Presently she is proceeding with Ph.D. under the supervision of Prof. S. G. Tilve and Prof. V. P. Kamat in department of chemistry, Goa University, Goa. Her re...
متن کاملBlood Spotlight
This spotlight review focuses on the second-generation proteasome inhibitor carfilzomib, which was recently approved by the US Food and Drug Administration for treatment of relapsed and refractory multiple myeloma patients who have received at least 2 prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the comple...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical and Translational Neuroscience
سال: 2018
ISSN: 2514-183X,2514-183X
DOI: 10.1177/2514183x18758525